One-step extrusion of concentrated lidocaine lipid nanocarrier (LNC) dispersions.

Int J Pharm

Dynation LLC, 1000 Westgate Drive, Suite 150N, St. Paul, MN 55114, United States; Superior Nano, 1313 Fairgrounds Road, Two Harbors, MN 55616, United States. Electronic address:

Published: November 2020

Lipid nanocarriers (LNCs) have been successfully produced by many methods including high pressure homogenization, sonication and microemulsification, but it remains very difficult to produce dispersions with greater than 30% LNCs, volume average particle diameter less than 150 nm, and concentration of drugs useful for topical products. This research is the first to propose and demonstrate extrusion to manufacture highly concentrated drug containing LNC dispersions continuously and economically in a single step. By treating crude emulsions in a twin-screw extruder which has sections for homogenizing, mixing and fast-cooling inside the extruder, lidocaine-loaded LNC dispersions were successfully generated with lipid concentration up to 60% and particle diameters less than 50 nm. Electrical conductivity and birefringence measurements indicate that in the lidocaine system, lamellar microemulsions are intermediate structures and compositions with low lipid concentrations that do not present evidence of lamellar structures fail to give nanoparticles when processed. This paper also presents a new method for measuring kinetics of drug release from nanoparticles based on pH stat titration. Sufficiently precise data from pH stat titration allows determination of rate laws for release occurring on a time scale of minutes versus hours or days. The release rate of lidocaine from extruded 35% lipid nanoparticles was constant (zero order release kinetics) through the first hour (40% of drug release), a valuable property for drug delivery.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijpharm.2020.119817DOI Listing

Publication Analysis

Top Keywords

lnc dispersions
12
drug release
8
stat titration
8
lipid
5
release
5
one-step extrusion
4
extrusion concentrated
4
concentrated lidocaine
4
lidocaine lipid
4
lipid nanocarrier
4

Similar Publications

Our research group previously studied the effectiveness of lipid-core nanocapsules (LNC) containing simvastatin (SV-LNC) in treating cognitive impairment in rats. While our results were promising, we needed to evaluate the potential toxicity of the nanoparticles themselves. This study aimed to compare the biochemical and hematological parameters of adult Wistar rats receiving LNC or SV-LNC to those receiving low doses of simvastatin crystals dispersed in a saline solution over 45 days.

View Article and Find Full Text PDF

Tuning perovskite nanocrystal superlattices for superradiance in the presence of disorder.

J Chem Phys

November 2023

Division of Chemical Physics, Department of Chemistry, Lund University, P.O. Box, 124, SE-221 00 Lund, Sweden.

The cooperative emission of interacting nanocrystals is an exciting topic fueled by recent reports of superfluorescence and superradiance in assemblies of perovskite nanocubes. Several studies estimated that coherent coupling is localized to a small fraction of nanocrystals (10-7-10-3) within the assembly, raising questions about the origins of localization and ways to overcome it. In this work, we examine single-excitation superradiance by calculating radiative decays and the distribution of superradiant wave function in two-dimensional CsPbBr3 nanocube superlattices.

View Article and Find Full Text PDF

Non-coding RNAs and exosomal non-coding RNAs in diabetic retinopathy: A narrative review.

Int J Biol Macromol

February 2024

Institute for Immunology and Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States. Electronic address:

Diabetic retinopathy (DR) is a devastating complication of diabetes, having extensive and resilient effects on those who suffer from it. As yet, the underlying cell mechanisms of this microvascular disorder are largely unclear. Recently, growing evidence suggests that epigenetic mechanisms can be responsible for gene deregulation leading to the alteration of key processes in the development and progression of DR, in addition to the widely recognized pathological mechanisms.

View Article and Find Full Text PDF

Fedratinib is an oral Janus kinase 2-selective inhibitor for the treatment of adult patients with intermediate-2 or high-risk myelofibrosis; however, some patients have difficulty with oral dosing. This randomized, phase 1, open-label, 2-part crossover study evaluated the relative bioavailability, safety, tolerability, taste, and palatability of fedratinib resulting from various alternative oral administration methods in healthy adults. Participants could receive fedratinib 400 mg orally as intact capsules along with a nutritional supplement; as contents of capsules dispersed in a nutritional supplement, delivered via nasogastric tube; or as a divided dose of 200 mg orally twice daily as intact capsules with a nutritional supplement.

View Article and Find Full Text PDF

Recently, cGMP analogues have been investigated for the treatment of inherited retinal degenerations (IRD) using intravitreal injections. However, higher vitreous elimination rates limit the possibility to treat the retina with small molecule drugs. Here, we investigated the potential of lipid nanocapsules (LNCs) as vehicles to reduce clearance and prolong the delivery of cGMP analogue, CN03 to the retinal photoreceptors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!